Biopharma Comebacks With Vincerx's Ahmed Hamdy, MD
Business Of Biotech
00:00
The Indications for the First Antibody Drug Conjugate in CLL
VIP 943 targets a CD123, which is highly expressed in AML and BALL and MDS. The second target is CXCR5, which is first in class, antibody drug conjugate targeting CX CR5. That is geared for an IND next year. I'm really excited about it, especially when we say the B cell world, who needs another drug in CLL is more or less cured. And obviously, it can work by itself or even in combinations with earlier lines of therapy,. BTK, one of my favorite compounds. If you combine it earlier on in the lines of therapy, you'd be able to get patients to complete remissions rather than prevent
Transcript
Play full episode
